Medlive is proud to share that three abstracts have been accepted for presentation at the upcoming San Antionio Breast Cancer Symposium, taking place December 9 – 12, 2025, in San Antonio, TX.
Accepted Posters
Abstract #2296
PI3K/AKT/mTOR Inhibitors in HR+/HER2- Breast Cancer: Bridging the Gap Between Evidence and Community Practice in Toxicity Management (24-MDL44)
Supported by AstraZeneca
Presentation: Wednesday, December 10, 2025 | 12:30 PM – 2:30 PM
(Virtual roundtable + Presentation)
Abstract #2518
Journeying Through the Spectrum of HER2 Expression Breast Cancer Clinic: Education Outcomes on Guiding Treatment Decisions (24-MDL12)
Supported by AstraZeneca/Daiichi Sankyo in partnership with Living Beyond Breast Cancer
Presentation: Friday, December 12, 2025 | 12:30 PM – 2:00 PM
Abstract #2501
Centering the Patient Experience within TNBC Care and Fostering Equity in the Hispanic and Latina Populations (24-MDL14)
Supported by Gilead in partnership with Surviving Breast Cancer and Salud America
Presentation: Wednesday, December 10, 2025 | 5:00 PM – 6:30 PM
All three posters will be presented by Medlive’s medical oncology team, highlighting data-driven perspectives on the evolving challenges and opportunities in breast cancer education and care delivery.
Jean A. Sachs, MSS, MLSP, Chief Executive Officer of Living Beyond Breast Cancer, had this to say about our shared mission:
“At Living Beyond Breast Cancer, our mission is to connect people with trusted information and a community of support—so no one faces breast cancer alone. Partnering with Medlive on education around HER2 expression reflects that mission in action. Together, we’re helping clinicians translate evolving science into better conversations and care decisions, ensuring patients receive treatments that align with their individual diagnosis and needs.”
To learn more about partnering with Medlive to develop impactful CME programs in oncology and other therapeutic areas, visit our Contact Us page to connect with our team.
